2011
DOI: 10.1128/cvi.00254-10
|View full text |Cite
|
Sign up to set email alerts
|

Intranasal Vaccination with the Recombinant Listeria monocytogenes ΔactA prfA*Mutant Elicits Robust Systemic and Pulmonary Cellular Responses and Secretory Mucosal IgA

Abstract: We previously showed that recombinant (r) Listeria monocytogenes carrying ⌬actA and a selected prfA* mutation (r-Listeria ⌬actA prfA*) secreted >100-fold more immunogen in broth culture than wild-type r-Listeria or r-Listeria ⌬actA and elicited much greater cellular and humoral immune responses than r-Listeria ⌬actA after intravenous vaccination of mice. Here, we conducted comparative studies evaluating vaccine-elicited immune responses in systemic and mucosal sites after intranasal, intravenous, intraperitone… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
16
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 17 publications
(16 citation statements)
references
References 33 publications
0
16
0
Order By: Relevance
“…Suppressive signalling may be reduced by using strains that contain a point mutation in the master virulence regulator PrfA that locks it in an active state, termed PrfA*. These strains escape more readily into the cytosol and are enhanced for CMI (Lauer et al, ; Qiu et al, ). Alternatively, pretreatment of L. monocytogenes with reducing agents, which mimic the reducing environment experienced by L. monocytogenes in the cytosol, can also preactivate PrfA (Portman, Dubensky, Peterson, Whiteley, & Portnoy, ).…”
Section: Monocytogenes Vaccinesmentioning
confidence: 99%
“…Suppressive signalling may be reduced by using strains that contain a point mutation in the master virulence regulator PrfA that locks it in an active state, termed PrfA*. These strains escape more readily into the cytosol and are enhanced for CMI (Lauer et al, ; Qiu et al, ). Alternatively, pretreatment of L. monocytogenes with reducing agents, which mimic the reducing environment experienced by L. monocytogenes in the cytosol, can also preactivate PrfA (Portman, Dubensky, Peterson, Whiteley, & Portnoy, ).…”
Section: Monocytogenes Vaccinesmentioning
confidence: 99%
“…This was done following the standard protocol as we and others previously described (29,30). To generate L. monocytogenes-infected targets, monocytes isolated from PBMCs were cultured for 3-4 d to generate monolayer macrophages.…”
Section: Measurement Of L Monocytogenes Cfus From Cultured Cells Conmentioning
confidence: 99%
“…Vaccination by different routes has also been shown to influence the efficacy of vaccines against parasitic, bacterial, and viral infections, as well as cancer (3,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). In the case of infections initiated in the skin by the bite of an insect vector, such as Yersinia, Plasmodium, Borrelia, and Leishmania infections (29), the use of an intradermal route of infection would appear to be critical, since the initial interaction between these pathogens and the host takes place primarily in the skin under natural conditions (11,15,(30)(31)(32).…”
mentioning
confidence: 99%